Hereditary Angioedema Market Expected to rise, 2034 | KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, expected to drive market

The Hereditary Angioedema market growth is driven by factors like increase in the prevalence of Hereditary Angioedema, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Hereditary Angioedema market report [https://www.delveinsight.com/report-store/hereditary-angioedema-hae-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Hereditary Angioedema market size, share, Hereditary Angioedema epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Hereditary Angioedema market size growth forward.

Some of the key highlights from the Hereditary Angioedema Market Insights Report:

*
Several key pharmaceutical companies, including KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, and others, are developing novel products to improve the Hereditary Angioedema treatment outlook.

*
In February 2024, BioCryst launched ORLADEYO (berotralstat) in Italy.

*
In January 2024, Ionis announced positive topline results from the Phase III OASIS-HAE study, which evaluated the investigational drug donidalorsen for hereditary angioedema (HAE). Following these promising findings, Ionis is preparing to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).

*
In December 2023, CSL Behring reported that the FDA had accepted a Biologics License Application (BLA) for garadacimab (CSL312), proposed as a monthly prophylactic treatment for HAE.

*
As per DelveInsight analysis, the Hereditary Angioedema market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Hereditary Angioedema Market Landscape [https://www.delveinsight.com/sample-request/hereditary-angioedema-hae-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Hereditary Angioedema Overview

Hereditary Angioedema (HAE) is a rare genetic condition characterized by vasogenic edema due to a deficiency of functional C1 inhibitor (C1-INH). This deficiency leads to recurrent episodes of localized subcutaneous or mucosal swelling, commonly affecting the skin, intestines, upper respiratory tract, and oropharynx.

Symptoms include sudden swelling around the eyes, face, and extremities, abdominal pain caused by bowel edema, and laryngeal edema, which can result in hoarseness, breathing difficulties, and potentially fatal outcomes. Early diagnosis and treatment are essential to improving quality of life and preventing life-threatening events, as even a single laryngeal edema episode can be fatal.

Diagnosis involves evaluating clinical symptoms, family history, and laboratory tests. Recurrent abdominal pain or edema without urticaria, especially in individuals with a family history of HAE, should raise suspicion of the condition.

Do you know the treatment paradigms for different countries? Download our Hereditary Angioedema Market Sample Report [https://www.delveinsight.com/report-store/hereditary-angioedema-hae-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Hereditary Angioedema Epidemiology Insights

*
In 2021, the United States had the highest number of diagnosed prevalent cases of Hereditary Angioedema (HAE) among the 7MM+China, with 7,614 cases. Within Europe, the UK reported the largest diagnosed prevalent population, with approximately 1,348 cases, followed by Germany with 1,266 cases. In contrast, Spain and Italy had the lowest diagnosed prevalent populations, each with approximately 942 cases.

Hereditary Angioedema Epidemiology Segmentation

DelveInsight's Hereditary Angioedema market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Hereditary Angioedema historical patient pools and forecasted Hereditary Angioedema patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Hereditary Angioedema Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

*
Hereditary Angioedema Prevalence

*
Age-Specific Hereditary Angioedema Prevalence

*
Gender-Specific Hereditary Angioedema Prevalence

*
Diagnosed and Treatable Cases of Hereditary Angioedema

Visit for more @ Hereditary Angioedema Epidemiological Insights [https://www.delveinsight.com/sample-request/hereditary-angioedema-hae-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Hereditary Angioedema Market Insights:

*
In 2021, the total market size for Hereditary Angioedema (HAE) in the 7MM+China was approximately USD 2,152 million, with steady growth anticipated through 2032 at a moderate CAGR. The United States dominated the market, accounting for around USD 1,769 million in 2021, and is projected to see continued growth over the forecast period (2022-2032). The combined market size of the EU4 and the UK was estimated at USD 347 million in 2021 and is expected to increase further by 2032.

Hereditary Angioedema Market Outlook

Although there is no cure for Hereditary Angioedema (HAE), various approaches can help prevent or manage swelling attacks. Several HAE-specific treatments are available, including attenuated androgens; however, access to some medications may be limited by regional availability, regulatory approvals, or cost. Other less-established options, such as antifibrinolytics and fresh frozen plasma, may also play a role in certain cases.

The HAE treatment landscape is broadly divided into two strategies: on-demand therapies, used to quickly alleviate and resolve angioedema symptoms during an attack, and prophylactic treatments. Long-term prophylaxis reduces the overall disease burden, while short-term or periprocedural prophylaxis is used before known triggers to prevent attacks.

Hereditary Angioedema Marketed Drugs

*
FIRAZYR: Shire/Takeda

*
ORLADEYO (berotralstat): BioCryst Ireland Limited

Hereditary Angioedema Emerging Drugs

*
Sebetralstat (KVD900): KalVista Pharmaceuticals

*
Garadacimab (CSL312): CSL Behring

Hereditary Angioedema Key Companies

*
KalVista Pharmaceuticals

*
Intellia Therapeutics

*
BioMarin Pharmaceutical

For more information, visit Hereditary Angioedema Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/hereditary-angioedema-hae-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Hereditary Angioedema Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Hereditary Angioedema, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Hereditary Angioedema epidemiology in the 7MM

*
Hereditary Angioedema marketed and emerging therapies

*
Hereditary Angioedema companies

*
Hereditary Angioedema market drivers and barriers

Table of Contents:

1 Hereditary Angioedema Market Key Comprehensive Insights

2 Hereditary Angioedema Market Report Introduction

3 Competitive Intelligence Analysis for Hereditary Angioedema

4 Hereditary Angioedema Market Analysis Overview at a Glance

5 Executive Summary of Hereditary Angioedema

6 Hereditary Angioedema Epidemiology and Market Methodology

7 Hereditary Angioedema Epidemiology and Patient Population

8 Hereditary Angioedema Patient Journey

9 Hereditary Angioedema Treatment Algorithm, Hereditary Angioedema Current Treatment, and Medical Practices

10 Key Endpoints in Hereditary Angioedema Clinical Trials

11 Hereditary Angioedema Marketed Therapies

12 Hereditary Angioedema Emerging Therapies

13 Hereditary Angioedema: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Hereditary Angioedema

16 Hereditary Angioedema Market Key Opinion Leaders Reviews

18 Hereditary Angioedema Market Drivers

19 Hereditary Angioedema Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Hereditary Angioedema Epidemiology 2034

DelveInsight's "Hereditary Angioedema - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Hereditary Angioedema epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Hereditary Angioedema Pipeline 2024

"Hereditary Angioedema Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hereditary Angioedema market. A detailed picture of the Hereditary Angioedema pipeline landscape is provided, which includes the disease overview and Hereditary Angioedema treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hereditary-angioedema-market-expected-to-rise-2034-kalvista-pharmaceuticals-intellia-therapeutics-biomarin-pharmaceutical-expected-to-drive-market]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.